Efficacy and Safety of An'Ningpai Expectorant in Non-CF Bronchiectasis

Summary

The objective of this study was to assess whether the long-term use of oral An'Ningpai Enteric Soft Capsuleson (300 mg, three times daily, 12 months) might reduce the incidence of exacerbations and improve the quality of life in patients with Non-CF bronchiectasis.

Timeline

Start

2021-01-01

Primary completion

2022-12-30

Completion

2023-06-30

Drugs

Indications